S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PMN · ProMIS Neurosciences Inc. Common Shares (ON)
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
ProMIS Neurosciences Inc (PMN)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$8.28
+0.07
(+0.85%)
● At close: October 20 at 4:00:00 PM EDT
DAY'S RANGE
$8.28
$8.28
$8.40
52-WEEK RANGE
$8.28
$6.27
$27.40
What's happening
- PMN is up 0.85% today, trading at $8.28. — Live quote
- Volume today (452) is well below its 3-month average of 71,080. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.28 actual vs. $-1.39 estimated (+8.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PMN
+18.45%
vs S&P 500
+5.67%
1-YEAR RETURN
PMN
-28.09%
vs S&P 500
-42.65%
6-MONTH RETURN
PMN
-31.67%
3-MONTH RETURN
PMN
-44.17%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.28
Est. $-1.39
BEAT +8.1%
2026-04-26 (Q1 2026)
$-1.26
Est. $-1.49
BEAT +15.5%
2026-01-26 (Q4 2025)
$-6.57
Est. $-4.93
MISS -33.4%
2025-10-26 (Q3 2025)
$-6.00
Est. $-6.14
BEAT +2.3%
Valuation Measures & Ratios
Enterprise Value4$19.1M
Forward P/E5—
PEG Ratio6-0.00
Price / Sales (TTM1)7254.86
Price / Book72.39
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-12900.00%
Operating Margin-12900.00%
Return on Equity (ROE8)-79.35%
Return on Assets (ROA9)-109.15%
Avg Volume (3M)71,080
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $122.7M | $84.5M | $506.6M | $17.0M | $24.3M |
| P/E | -2.94 | -2.27 | -25.63 | -1.57 | -5.62 |
| Price/Book | 2.48 | 1.39 | 55.14 | -44.40 | 2.57 |
| ROE | -84.36% | -61.41% | -215.18% | 2826.29% | -45.72% |
| ROA | -73.50% | -55.32% | -92.13% | -113.70% | -31.74% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short238,584
Change from Prior Settlement-0.59%
% of Float—
Days to Cover (Short Ratio)7.12
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -12900.0%. Finnhub fundamentals ↗
- Trailing 52-week price return is -28.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PMN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$12.3M | -$8.6M | -$11.8M | -$10.2M | -$7.5M | -$4.4M | -$2.7M | -$3.7M |
| Net income | -$11.7M | -$8.2M | -$11.6M | -$10.1M | -$7.3M | $9.3M | -$2.6M | -$3.6M |
| EPS (diluted) | $-1.28 | $-1.26 | $-0.24 | $-7.26 | $-5.27 | $0.31 | $-0.13 | $-0.19 |
| EPS (basic) | $-1.28 | $-1.26 | $-0.24 | $-7.26 | $-5.27 | $0.31 | $-0.13 | $-0.19 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $56.7M | $67.4M | $9.2M | $21.5M | $9.5M | $13.6M | $18.9M | $24.5M |
| Total liabilities | $7.3M | $6.7M | $10.4M | $12.3M | $9.9M | $4.2M | $2.4M | $17.2M |
| Stockholders' equity | $49.4M | $60.7M | -$1.3M | $9.2M | -$382.6K | $9.5M | $16.5M | $7.3M |
| Total current assets | $56.7M | $65.6M | $9.2M | $21.5M | $9.5M | $13.6M | $18.9M | $24.5M |
| Total current liabilities | $7.2M | $6.6M | $10.4M | $12.2M | $9.8M | $4.1M | $2.2M | $2.6M |
| Cash & equivalents | $53.4M | $63.8M | $6.1M | $15.4M | $4.5M | $8.4M | $13.3M | $21.5M |
| Marketable securities (current) | $33.8K | $33.8K | $33.8K | $33.1K | $33.1K | $33.1K | $33.1K | $32.4K |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Accounts payable | $1.8M | $1.7M | $2.5M | $4.2M | $2.8M | $1.2M | $1.7M | $1.6M |
| Accrued liabilities | $5.4M | $4.9M | $7.9M | $8.0M | $7.0M | $2.9M | $481.0K | $1.1M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$150.4M | -$138.7M | -$130.4M | -$119.7M | -$108.2M | -$98.0M | -$90.7M | -$90.4M |
| Accumulated other comprehensive income (loss) | -$371.2K | -$371.2K | -$371.2K | -$371.2K | -$371.2K | -$371.2K | -$371.2K | -$371.2K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.4M | -$12.4M | -$9.3M | -$10.1M | -$3.9M | -$4.9M | -$8.7M | -$6.7M |
| Investing cash flow | — | — | -$702 | — | — | — | -$693 | — |
| Financing cash flow | $0 | $70.1M | -$1 | $20.9M | — | — | $470.0K | $27.2M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $408.9K | $189.4K | $203.2K | $197.1K | $212.0K | $245.3K | $623.2K | $121.0K |
| Change in accounts payable | $76.7K | -$826.6K | -$1.7M | $1.4M | $1.6M | -$537.3K | $162.2K | -$439.9K |
| Other investing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$40.2M | -$16.8M | -$14.3M | -$23.4M | -$8.3M |
| Net income | -$39.7M | $2.8M | -$13.2M | -$18.1M | -$9.8M |
| EPS (diluted) | $-22.61 | $2.63 | $-1.07 | $-2.41 | $-1.69 |
| EPS (basic) | $-22.61 | $2.68 | $-1.07 | $-2.41 | $-1.69 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $9.2M | $18.9M | $13.6M | $6.9M | $17.7M |
| Total liabilities | $10.4M | $2.4M | $9.9M | $8.3M | $12.1M |
| Stockholders' equity | -$1.3M | $16.5M | $3.8M | -$1.3M | $5.7M |
| Total current assets | $9.2M | $18.9M | $13.6M | $6.9M | $17.7M |
| Total current liabilities | $10.4M | $2.2M | $9.3M | $6.4M | $929.1K |
| Cash & equivalents | $6.1M | $13.3M | $12.6M | $5.9M | $16.9M |
| Marketable securities (current) | $33.8K | $33.1K | $32.4K | $31.0K | $33.2K |
| Property, plant & equipment | — | — | — | $321 | $4.7K |
| Intangible assets | — | — | — | $20.8K | $27.6K |
| Accounts payable | $2.5M | $1.7M | $7.8M | $3.0M | $409.0K |
| Accrued liabilities | $7.9M | $481.0K | $1.5M | $3.4M | $520.1K |
| Long-term debt | — | — | $0 | — | $3.9M |
| Retained earnings | -$130.4M | -$90.7M | -$93.5M | -$80.3M | -$62.2M |
| Accumulated other comprehensive income (loss) | -$371.2K | -$371.2K | -$371.2K | -$195.4K | -$187.9K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$28.1M | -$27.2M | -$10.8M | -$17.0M | -$9.3M |
| Investing cash flow | -$702 | -$693 | -$1.3K | -$2.0K | $94.6K |
| Financing cash flow | $20.9M | $27.9M | $17.7M | $6.5M | $25.5M |
| Free cash flow | — | — | — | -$17.0M | -$9.3M |
| Capital expenditures | — | — | — | $2.0K | $6.0K |
| Share-based compensation | $857.6K | $825.8K | $271.5K | $487.6K | $515.6K |
| Change in accounts payable | $806.0K | -$6.1M | $5.0M | $2.7M | -$31.7K |
| Other investing activities | — | — | — | — | -$2.4K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PMN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-07-25 to 2026-08-05
Recent transactions
- Insiders have net bought 6,280 shares over the last 182 days, across 2 purchases and 0 sales.
- Most recent: Kaplan Johanne (Chief Development Officer) — Open market purchase of 2,280 shares on 2026-08-05.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)6,280 sh(2 txns)
Sales (open market)0 sh(0 txns)
Net Shares+6,280
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kaplan Johanne | Chief Development Officer | Open market purchase | 2026-08-05 | 2,280 |
| Kirwin Patrick D. | Director | Open market purchase | 2026-04-22 | 4,000 |
| Williams Eugene | Director | Open market purchase | 2026-03-05 | 2,000 |
| Cashman Neil | Chief Scientific Officer | Grant / award | 2026-02-03 | 4,122 |
| Warma Neil K | Chief Executive Officer | Grant / award | 2026-02-03 | 6,183 |
| Milbury Max A. | Principal Accounting Officer | Grant / award | 2026-02-03 | 6,595 |
| ABG Management Ltd. | 10% owner | Open market purchase | 2026-02-03 | 700,741 |
| Jeremy M. Sclar 2012 Irrevocable Family Trust | 10% owner | In-the-money option exercise | 2025-07-25 | 697,674 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-05 | Kaplan Johanne | Chief Development Officer | Open market purchase | 2,280 | $13.30 |
| 2026-04-22 | Kirwin Patrick D. | Director | Open market purchase | 4,000 | $11.33 |
| 2026-03-05 | Williams Eugene | Director | Open market purchase | 2,000 | $24.40 |
| 2026-03-04 | Williams Eugene | Director | Open market purchase | 2,000 | $24.00 |
| 2026-03-03 | Williams Eugene | Director | Open market purchase | 1,000 | $21.89 |
| 2026-03-02 | Williams Eugene | Director | Open market purchase | 1,000 | $22.53 |
| 2026-02-19 | Kaplan Johanne | Chief Development Officer | Open market purchase | 1,629 | $15.35 |
| 2026-02-03 | Cashman Neil | Chief Scientific Officer | Grant / award | 4,122 | $12.13 |
| 2026-02-03 | Kaplan Johanne | Chief Development Officer | Grant / award | 2,060 | $12.13 |
| 2026-02-03 | Warma Neil K | Chief Executive Officer | Grant / award | 6,183 | $12.13 |
| 2026-02-03 | Milbury Max A. | Principal Accounting Officer | Grant / award | 6,595 | $12.13 |
| 2026-02-03 | Kirwin Patrick D. | Director | Grant / award | 3,050 | $12.13 |
| 2026-02-03 | ABG Management Ltd. | 10% owner | Open market purchase | 700,741 | $12.13 |
| 2025-10-03 | Milbury Max A. | Principal Accounting Officer | Open market purchase | 30,392 | $0.49 |
| 2025-07-25 | Jeremy M. Sclar 2012 Irrevocable Family Trust | 10% owner | In-the-money option exercise | 697,674 | — |
| 2025-07-25 | Jeremy M. Sclar 2012 Irrevocable Family Trust | 10% owner | In-the-money option exercise | 697,674 | — |
| 2025-07-25 | Jeremy M. Sclar 2012 Irrevocable Family Trust | 10% owner | In-the-money option exercise | 697,674 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:41 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-05 | View on SEC.gov → |
| 2026-07-28 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
Recent news
Headlines about PMN (ProMIS Neurosciences Inc. Common Shares (ON)). Links open the publisher — we don’t host full articles.
-
Can Higher Admissions Offset Rising Costs in UHS' Q3 Earnings?
Yahoo · 2026-10-21 -
Trading Systems Reacting to (PMN) Volatility
Stock Traders Daily · 2026-10-18 -
CABA,PFX,SKWD,FFIN,ELUT,ZBIO,HYPD,BLCO,ALT,TSLX,ENTX,BLIN,PMN,TBBK,SSP,PCF,GAIA,SPMC,GEF-B,APCX,IRIX,RAL,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-18 -
CABA,SKWD,PFX,FFIN,ELUT,HYPD,ZBIO,BLCO,ALT,ENTX,LEE,TBBK,PMN,BLIN,SSP,PCF,GAIA,MDRR,GEF-B,SPMC,IRIX,APCX,RAL | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-15 -
CABA,PFX,SKWD,ELUT,ZBIO,HYPD,BLCO,ALT,LEE,ENTX,BLIN,TBBK,PMN,SSP,PCF,MDRR,GAIA,SPMC,GEF-B,APCX,IRIX,RAL,RNXT | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-15 -
CABA,SKWD,PFX,FFIN,ELUT,HYPD,ZBIO,ALT,BLCO,ENTX,LEE,TBBK,BLIN,PMN,SSP,PCF,GAIA,MDRR,SPMC,GEF-B,IRIX,APCX,RAL | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-15 -
CABA,PFX,SKWD,FFIN,ELUT,HYPD,ZBIO,ALT,BLCO,LEE,ENTX,BLIN,TBBK,PMN,SSP,PCF,MDRR,GAIA,SPMC,GEF-B,IRIX,APCX,RAL | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-15 -
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Yahoo Finance · 2026-10-06
No headlines in this category right now — try “All”.